Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06435260
PHASE2

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

Sponsor: Hebei Medical University Fourth Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of Borderline Resectable/locally advanced pancreatic cancer.

Official title: To Explore the Efficacy of Hypofractionated Radiotherapy Followed by AG Regimen Chemotherapy Plus Camrelizumab Immunotherapy as Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Cancer

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2024-08-01

Completion Date

2027-06-01

Last Updated

2025-06-26

Healthy Volunteers

No

Interventions

DRUG

Camrelizumab+chemotherapy

Chemotherapy combined with ICIs was started 5-7 days after the completion of radiotherapy: AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles. Camrelizumab: 200mg, iv, 30min, q3w, 4 cycles.

RADIATION

hypofractionated radiotherapy

Hypofractionated radiotherapy:PGTV=30Gy/5F(PTV≥25Gy/5F),

Locations (1)

Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, China